In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 7 selected

Guidance programme

Showing 1 to 10 of 350

TitleTypeExpected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510Technology appraisal guidance
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]Technology appraisal guidanceTBC
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]Technology appraisal guidance
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidanceTBC
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy [ID6354]Technology appraisal guidance
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575Technology appraisal guidanceTBC
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All